GlassScriptPhysician profile
Ambra Nida
NPI 1558517060
$812.32
in general payments reported to CMS, 2019-2025
11 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.20 · 2022: $105 · 2023: $81.86 · 2024: $76.20 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $393.70 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $148.21 | 2024-2025 | Glassia, Aralast |
| Philips North America LLC | $51.93 | 2025 | Vest Therapy Und |
| Baxter Healthcare | $48.06 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $39.51 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $31.76 | 2022-2023 | Mounjaro |
| Novo Nordisk INC | $26.47 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.98 | 2022 | |
| Viatris Specialty LLC | $18.61 | 2025 | Yupelri |
| Abbvie INC. | $14.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.89 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambra Nida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.